Skip to main content
SpringerLink
Log in

The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma

  • Published:
Abdominal Imaging Aims and scope Submit manuscript

Abstract

Objective

To evaluate the value of the gadobenate dimeglumine-enhanced hepatobiliary-phase magnetic resonance (MR) imaging for the differentiation of scirrhous hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) with or without HCC.

Materials and methods

We retrospectively evaluated unenhanced and gadobenate dimeglumine-enhanced dynamic and hepatobiliary-phase MR images of five patients with scirrhous HCCs and 29 patients with 57 CCs with or without HCC with statistical analysis using Fisher’s exact test.

Results

Peripheral hyperintensity compared with the center on T2-weighted images was more frequent for scirrhous HCCs (n = 3, 60%) as compared to CCs with or without HCC (n = 7, 12%) (P = 0.026). There was no significant difference in the gadobenate dimeglumine-enhanced dynamic imaging of both scirrhous HCC and CC with or without HCC (P > 0.05). On hepatobiliary-phase images, scirrhous HCC showed no target appearance as compared with that 50 (87.7%) CCs with or without HCC showed target appearance (P < 0.001).

Conclusion

Although both scirrhous HCC and CC with or without HCC show similar imaging findings on unenhanced and gadobenate dimeglumine-enhanced dynamic MR images, gadobenate dimeglumine-enhanced hepatobiliary-phase MR images may be helpful to differentiate scirrhous HCC from CC with or without HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol 1949; 25:647–655.

    CAS  PubMed  Google Scholar 

  2. [No authors listed] (1990) Primary liver cancer in Japan: clinicopathologic features and results of surgical treatment—Liver Cancer Study Group of Japan. Ann Surg 221:277–287

    Google Scholar 

  3. Lee WS, Lee KW, Heo JS, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today 2006; 36:892–897.

    Article  PubMed  Google Scholar 

  4. Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 2003; 33:283–287.

    Article  PubMed  Google Scholar 

  5. Okamura N, Yoshida M, Shibuya A, et al. Cellular and stromal characteristics in the scirrhous hepatocellular carcinoma: comparison with hepatocellular carcinomas and intrahepatic cholangiocarcinomas. Pathology international 2005; 55:724–731.

    Article  CAS  PubMed  Google Scholar 

  6. Matsuura S, Aishima S, Taguchi K, et al. ‘Scirrhous’ type hepatocellular carcinoma: a special reference to expression of cytokeratin 7 and hepatocyte paraffin 1. Histopathology 2005; 47:382–390.

    Article  CAS  PubMed  Google Scholar 

  7. Kurogi M, Nakashima O, Miyaaki H, Fujimoto M, Kojiro M. Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol 2006; 21:1470–1477.

    PubMed  Google Scholar 

  8. Kim SH, Lim HK, Lee WJ, Choi D, Park CK. Scirrhous hepatocellular carcinoma: Comparison with usual hepatocellular carcinoma based on CT-pathologic features and long-term results after curative resection. Eur J Radiol 2009; 69:123-130.

    Article  PubMed  Google Scholar 

  9. Valls C, Gumà A, Puig I, et al. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom Imaging 2000; 25:490–496.

    Article  CAS  PubMed  Google Scholar 

  10. Murakami T, Nakamura H, Tsuda K, et al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging 1995; 5:165–170.

    Article  CAS  PubMed  Google Scholar 

  11. Soyer P, Bluemke DA, Reichle R, et al. Imaging of intrahepatic cholangiocarcinoma: 1. Peripheral cholangiocarcinoma. AJR 1995; 165:1427–1431.

    CAS  PubMed  Google Scholar 

  12. Goshima S, Kanematsu M, Yamada T, et al. Small scirrhous hepatocellular carcinoma with central scar: MR imaging findings. J Magn Reson Imaging 2002; 16:741–745.

    Article  PubMed  Google Scholar 

  13. Manfredi R, Barbaro B, Masselli G, Vecchioli A, Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis 2004; 24:155–164.

    Article  PubMed  Google Scholar 

  14. Maetani Y, Itoh K, Watanabe C, et al. MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR 2001; 176:1499–1507.

    CAS  PubMed  Google Scholar 

  15. Murakami T, Kim T, Tomoda K, et al. Combined hepatocellular and cholangiocellular carcinoma. Radiat med 1997; 15:243–246.

    CAS  PubMed  Google Scholar 

  16. Gabata T, Matsui O, Kadoya M, et al. Delayed MR imaging of the liver: correlation of delayed enhancement of hepatic tumors and pathologic appearance. Abdom Imaging 1998; 23:309–313.

    Article  CAS  PubMed  Google Scholar 

  17. Peterson MS, Murakami T, Baron RL. MR imaging patterns of gadolinium retention within liver neoplasms. Abdom Imaging 1998; 23:592–599.

    Article  CAS  PubMed  Google Scholar 

  18. Spinazzi A, Lorusso V, Pirovano G, Kirchin MA. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine. Acad Radiol 1999; 6:282–291.

    Article  CAS  PubMed  Google Scholar 

  19. Kirchin MA, Pirovano GP, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1998; 33:798–809.

    Article  CAS  PubMed  Google Scholar 

  20. Caudana R, Morana G, Pirovano GP, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)-preliminary results of phase II clinical application. Radiology 1996; 199:513–520.

    CAS  PubMed  Google Scholar 

  21. Spinazzi A, Lorusso V, Pirovano G, et al. (1998) Multihance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 5(1):S86–S89.

    Article  PubMed  Google Scholar 

  22. Schneider G, Altmeyer K, kirchin MA, et al. Evaluation of a novel time-efficient protocol for gadobenate dimeglumine (Gd-BOPTA)-enhanced liver magnetic resonance imaging. Invest Radiol 2007;42:105–115.

    Article  CAS  PubMed  Google Scholar 

  23. Grazioli L, Morana G, Kirchin MA, et al. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236:166–177.

    Article  PubMed  Google Scholar 

  24. Goodman ZD, Ishak KG, Langloss JM, Sesterhenn IA, Rabin L. Combined hepatocellular-cholangiocarcinoma. a histologic and immunohistochemical study. Cancer 1985; 55:124–135.

    Article  CAS  PubMed  Google Scholar 

  25. Asayama Y, Yoshimitsu K, Irie H, et al. Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology 2006; 238:150–155.

    Article  PubMed  Google Scholar 

  26. Nishie A, Yoshimitsu K, Asayama Y, et al. Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings. AJR 2005; 184:1157–1162.

    PubMed  Google Scholar 

  27. Muramatsu Y, Takayasu K, Moriyama N, et al. Peripheral low-density area of hepatic tumors: CT-pathologic correlation. Radiology 1986; 160:49–52.

    CAS  PubMed  Google Scholar 

  28. Mahfouz AE, Hamm B, Wolf KJ. Peripheral washout: a sign of malignancy on dynamic gadolinium-enhanced MR images of focal liver lesions. Radiology 1994; 190:49–52.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50, Ilwon-dong, Gangnam-gu, Seoul, 135-710, South Korea

    Tae Yeon Jeon, Seong Hyun Kim, Won Jae Lee & Hyo K. Lim

Authors
  1. Tae Yeon Jeon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seong Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Won Jae Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hyo K. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seong Hyun Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jeon, T.Y., Kim, S.H., Lee, W.J. et al. The value of gadobenate dimeglumine-enhanced hepatobiliary-phase MR imaging for the differentiation of scirrhous hepatocellular carcinoma and cholangiocarcinoma with or without hepatocellular carcinoma. Abdom Imaging 35, 337–345 (2010). https://doi.org/10.1007/s00261-009-9509-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00261-009-9509-8

Keywords

Search

Navigation